ClinConnect ClinConnect Logo
Search / Trial NCT05384509

(COVID-19) Longitudinal Neutralizing Antibody Titers in Cancer Patients Receiving Different Anti-caner Therapies

Launched by CHANG GUNG MEMORIAL HOSPITAL · May 18, 2022

Trial Information

Current as of August 21, 2025

Recruiting

Keywords

Immunotherapy Chemotherapy Targeted Therapy Covid 19 Vaccination Neutralizing Antibody Titers Spike Protein Antibody Titers

ClinConnect Summary

This clinical trial is studying how cancer patients respond to COVID-19 vaccination, specifically looking at the levels of antibodies produced after receiving the vaccine. Since patients with cancer are at higher risk for serious illness from COVID-19, understanding how well the vaccine works for them is very important. The study includes patients with various types of cancer who are receiving different treatments, such as chemotherapy, immunotherapy, or targeted therapy, as well as healthy volunteers.

To be eligible for this trial, participants must be over 20 years old and either currently undergoing cancer treatment or have been cancer-free for at least six months. They should also have been fully vaccinated against COVID-19 or be willing to get vaccinated during the study. Participants will provide blood samples to check their antibody levels and will have regular follow-ups to monitor their health. It's important for potential participants to know that they can withdraw from the study at any time if they choose to do so.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. adults \>20 years old;
  • 2. cancer patients under active anti-cancer therapy, including chemotherapy (n=80), targeted therapy (n=80) and immunotherapy (n=80); and cancer patients have been disease-free for ≥ 6 months (n=80)
  • 3. cancer patients who were full vaccinated with any brand of vaccines or cancer patients who were unvaccinated agree to complete full vaccination later.
  • 4. patients who agreed with the content of informed consent of the study protocol.
  • Exclusion Criteria:
  • 1. Patients who refused the protocol of N-antibody test and Out-Patient Departments follow-up.
  • 2. The investigators suggest to withdraw.
  • 3. Patient asked to withdraw from the trial at any timepoints.

About Chang Gung Memorial Hospital

Chang Gung Memorial Hospital, one of the largest healthcare organizations in Taiwan, is renowned for its commitment to advancing medical research and improving patient care. As a clinical trial sponsor, the hospital leverages its extensive clinical expertise and state-of-the-art facilities to conduct innovative research across various medical disciplines. With a focus on collaboration and ethical practices, Chang Gung Memorial Hospital aims to contribute to the global body of medical knowledge through rigorous clinical trials that enhance treatment options and improve health outcomes for patients.

Locations

New Taipei City, , Taiwan

Patients applied

0 patients applied

Trial Officials

Chia-Hsun Hsieh, PhD

Study Director

Professor Attending Physicians

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials